Aperio Group
ACHN

Aperio Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Aperio Group’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,635
Closed -$76K – 2446
2019
Q4 		$76K Buy
12,635
+1,363
+12% +$7.89K ﹤0.01% 2284
2019
Q3 		$41K Buy
11,272
+6,080
+117% +$23.4K ﹤0.01% 2287
2019
Q2 		$14K Buy
+5,192
New +$15.3K ﹤0.01% 2745
2016
Q1 		– Sell
-11,644
Closed -$126K – 2085
2015
Q4 		$126K Buy
11,644
+461
+4% +$4.19K ﹤0.01% 1901
2015
Q3 		$77K Buy
11,183
+523
+5% +$4.26K ﹤0.01% 1883
2015
Q2 		$94K Sell
10,660
-10,878
-51% -$103K ﹤0.01% 1952
2015
Q1 		$212K Buy
21,538
+5,293
+33% +$66.1K ﹤0.01% 1800
2014
Q4 		$199K Buy
16,245
+5,863
+56% +$71.6K ﹤0.01% 1752
2014
Q3 		$104K Buy
+10,382
New +$96.4K ﹤0.01% 1687

Aperio Group's ACHN Position: Q1 2020 in Review

Aperio Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 12,635 shares — an estimated $76K sold.

Aperio Group first reported a position in ACHN in Q3 2014 and held it in 9 quarters. The position peaked at $212K in Q1 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

  • Aperio Group reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Aperio Group sold 12,635 Achillion Pharmaceuticals shares in Q1 2020, an estimated $76K.
  • Aperio Group first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 9 quarters.
  • Aperio Group's Achillion Pharmaceuticals position peaked at $212K in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on Aperio Group's 13F filing for Q1 2020, filed 5 May 2020.